Clinical Research
Total Trials
14
As Lead Sponsor
10
As Collaborator
4
Total Enrollment
2,162
NCT00565630
Using Device Delivering Ophthalmic Solution in a Spray Form Instead of Eye Drops
Phase: N/A
Role: Lead Sponsor
Start: Jan 31, 2008
Completion: Mar 31, 2008
NCT00666042
Bioequivalence of Eye Drops and Spray Administration of Vigamox
Start: Feb 28, 2009
Completion: May 31, 2009
NCT01962961
N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults
Phase: Phase 1/2
Role: Collaborator
Start: Oct 31, 2013
Completion: Oct 31, 2015
NCT03400189
Pharmacokinetics and Tolerability of Sulthiame
Phase: Phase 1
Start: Feb 12, 2018
Completion: Aug 30, 2018
NCT03512015
A Mobile Supportive Care App for Patients With Metastatic Lung Cancer
Start: May 15, 2018
Completion: Jun 30, 2020
NCT04277156
L Rhamnosus ATCC 53103 & L Reuteri DSM 29063 Compared With L Rhamnosus ATCC 53103 for Preventing AAD in Children
Start: Feb 29, 2020
Completion: Dec 31, 2023
NCT03644706
Study Evaluating Subjects With Distal Renal Tubular Acidosis
Phase: Phase 3
Start: Sep 20, 2021
Completion: Dec 20, 2023
NCT05134012
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
Start: May 8, 2022
Completion: Dec 31, 2026
NCT03831152
Extension Study in Primary Distal Renal Tubular Acidosis
Start: Dec 20, 2023
Completion: Mar 31, 2025
NCT04147871
Study Evaluating Patients With Cystinuria and Efficacy and Safety Exploratory Study in the Youngest Children
Phase: Phase 2/3
Start: Mar 1, 2024
Completion: Jun 1, 2025
NCT06329401
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Phase: Phase 2
Start: Apr 3, 2024
Completion: Apr 30, 2026
NCT04137978
Study Evaluating Patients With Cystinuria
Start: May 1, 2024
Completion: Aug 31, 2025
NCT06951217
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Start: Apr 17, 2025
Completion: Dec 31, 2031
NCT07194382
AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF
Start: Jan 31, 2026
Completion: Jun 30, 2027
Loading map...